Patent intelligence · US
US 11702423
BRM targeting compounds and associated methods of use
BRM targeting compounds and associated methods of use
Patent details — US 11702423
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2023
- Expiration
- Jul 13, 2043
- Applicant
- Prelude Therapeutics, Incorporated
- Claims
- 18
- CPC classes
- A61P, A61P35/00, A61P35/02
Quick answer
US 11702423 (BRM targeting compounds and associated methods of use) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Prelude Therapeutics, Incorporated
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P35/00, A61P35/02
More from Prelude Therapeutics, Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12414953
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 12129262
CDK inhibitors and their use as pharmaceuticals
granted -
US 11939340
CDK inhibitors and their use as pharmaceuticals
granted -
US 11685744
CDK inhibitors and their use as pharmaceuticals
granted -
US 11673893
CDK inhibitors and their use as pharmaceuticals
granted -
US 11622970
BCL-2 inhibitors and their use as pharmaceuticals
granted -
US 11524962
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
granted
Related coverage
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
CMS is proposing a Medicare drug price rule that could shape the outlook for subcutaneous Keytruda and Opdivo. The products are expected to be eligible for selection in the 2027 negotiation round for IPAY 2029.
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. The catalyst is based on phase 3 LITESPARK-022 data and adds another regulatory milestone for belzutifan.
FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma. The move extends Merck’s renal cancer catalyst path after evidence showed improved disease-free survival versus pembrolizumab alone.
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
Frequently asked questions
What is US patent 11702423?
US 11702423 (BRM targeting compounds and associated methods of use) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11702423?
Prelude Therapeutics, Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 11702423 expire?
Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.